Tags

Type your tag names separated by a space and hit enter

No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial.
Clin Exp Allergy. 2006 Jul; 36(7):899-906.CE

Abstract

BACKGROUND

Studies have been performed suggesting that administration of probiotics may have therapeutic and/or preventive benefits in the development of sensitization and atopic disease, particularly in infants with atopic dermatitis (AD).

OBJECTIVE

The purpose of this study was to evaluate the clinical and immunological effects of supplementation of a hydrolysed formula with two probiotic strains of bacteria on symptoms of AD in infancy.

METHODS

We conducted a randomized, double-blind, placebo-controlled study. After 4-6 weeks of baseline and double-blind, placebo-controlled challenges for diagnosis of cow's milk allergy (CMA), infants less than 5 months old with AD received a hydrolysed whey-based formula as placebo (n = 17), or supplemented with either Lactobacillus rhamnosus (n = 17) or Lactobacillus GG (n = 16) for 3 months. Before, during and after intervention, the clinical severity of AD was evaluated using SCORing index Atopic Dermatitis (SCORAD). Allergic sensitization was evaluated by measurement of total IgE and a panel of food-specific IgEs as well as skin prick testing for cow's milk. Inflammatory parameters were blood eosinophils, eosinophil protein X in urine, fecal alpha-1-antitrypsin and production of IL-4, IL-5 and IFN-gamma by peripheral blood mononuclear cells after polyclonal stimulation.

RESULTS

No statistically significant effects of probiotic supplementation on SCORAD, sensitization, inflammatory parameters or cytokine production between groups were found. Only four infants were diagnosed with CMA.

CONCLUSION

We found no clinical or immunological effect of the probiotic bacteria used in infants with AD. Our results indicate that oral supplementation with these probiotic bacterial strains will not have a significant impact on the symptoms of infantile AD.

Authors+Show Affiliations

Department of Paediatrics, Division of Paediatric Pulmonology, University Medical Center Groningen, Beatrix Children's Hospital, Groningen, The Netherlands. m.l.brouwer@bkk.umbgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16839405

Citation

Brouwer, M L., et al. "No Effects of Probiotics On Atopic Dermatitis in Infancy: a Randomized Placebo-controlled Trial." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 36, no. 7, 2006, pp. 899-906.
Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy. 2006;36(7):899-906.
Brouwer, M. L., Wolt-Plompen, S. A., Dubois, A. E., van der Heide, S., Jansen, D. F., Hoijer, M. A., Kauffman, H. F., & Duiverman, E. J. (2006). No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 36(7), 899-906.
Brouwer ML, et al. No Effects of Probiotics On Atopic Dermatitis in Infancy: a Randomized Placebo-controlled Trial. Clin Exp Allergy. 2006;36(7):899-906. PubMed PMID: 16839405.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. AU - Brouwer,M L, AU - Wolt-Plompen,S A A, AU - Dubois,A E J, AU - van der Heide,S, AU - Jansen,D F, AU - Hoijer,M A, AU - Kauffman,H F, AU - Duiverman,E J, PY - 2006/7/15/pubmed PY - 2007/2/23/medline PY - 2006/7/15/entrez SP - 899 EP - 906 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 36 IS - 7 N2 - BACKGROUND: Studies have been performed suggesting that administration of probiotics may have therapeutic and/or preventive benefits in the development of sensitization and atopic disease, particularly in infants with atopic dermatitis (AD). OBJECTIVE: The purpose of this study was to evaluate the clinical and immunological effects of supplementation of a hydrolysed formula with two probiotic strains of bacteria on symptoms of AD in infancy. METHODS: We conducted a randomized, double-blind, placebo-controlled study. After 4-6 weeks of baseline and double-blind, placebo-controlled challenges for diagnosis of cow's milk allergy (CMA), infants less than 5 months old with AD received a hydrolysed whey-based formula as placebo (n = 17), or supplemented with either Lactobacillus rhamnosus (n = 17) or Lactobacillus GG (n = 16) for 3 months. Before, during and after intervention, the clinical severity of AD was evaluated using SCORing index Atopic Dermatitis (SCORAD). Allergic sensitization was evaluated by measurement of total IgE and a panel of food-specific IgEs as well as skin prick testing for cow's milk. Inflammatory parameters were blood eosinophils, eosinophil protein X in urine, fecal alpha-1-antitrypsin and production of IL-4, IL-5 and IFN-gamma by peripheral blood mononuclear cells after polyclonal stimulation. RESULTS: No statistically significant effects of probiotic supplementation on SCORAD, sensitization, inflammatory parameters or cytokine production between groups were found. Only four infants were diagnosed with CMA. CONCLUSION: We found no clinical or immunological effect of the probiotic bacteria used in infants with AD. Our results indicate that oral supplementation with these probiotic bacterial strains will not have a significant impact on the symptoms of infantile AD. SN - 0954-7894 UR - https://www.unboundmedicine.com/medline/citation/16839405/No_effects_of_probiotics_on_atopic_dermatitis_in_infancy:_a_randomized_placebo_controlled_trial_ L2 - https://doi.org/10.1111/j.1365-2222.2006.02513.x DB - PRIME DP - Unbound Medicine ER -